{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:49:29Z","timestamp":1791920969123,"version":"4.3.4"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006348","name":"Delaney AIDS Research Enterprise","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI126611"],"award-info":[{"award-number":["UM1AI126611"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.coviro.2019.03.004","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T13:08:44Z","timestamp":1556543324000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Between a shock and a hard place: challenges and developments in HIV latency reversal"],"prefix":"10.1016","volume":"38","author":[{"given":"Jennifer M","family":"Zerbato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison V","family":"Purves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon R","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2019.03.004_bib0005","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure","volume":"155","author":"Ho","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2019.03.004_bib0010","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.4156","article-title":"Defective proviruses rapidly accumulate during acute HIV-1 infection","volume":"22","author":"Bruner","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.03.004_bib0015","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","article-title":"A quantitative approach for measuring the reservoir of latent HIV-1 proviruses","volume":"566","author":"Bruner","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.03.004_bib0020","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.03.004_bib0025","doi-asserted-by":"crossref","first-page":"14070","DOI":"10.1128\/JVI.01900-14","article-title":"Quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells","volume":"88","author":"Soriano-Sarabia","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nm.3445","article-title":"HIV-1 persistence in CD4+ T cells with stem cell-like properties","volume":"20","author":"Buzon","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.03.004_bib0035","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz108","article-title":"Naive CD4+ T cells harbor a large inducible reservoir of latent, replication-competent HIV-1","author":"Zerbato","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2019.03.004_bib0040","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3390\/v6041837","article-title":"HIV-1 latency in monocytes\/macrophages","volume":"6","author":"Kumar","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2019.03.004_bib0045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.21697","article-title":"Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia","volume":"66","author":"Churchill","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0050","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/mi.2013.127","article-title":"Small alveolar macrophages are infected preferentially by HIV and exhibit impaired phagocytic function","volume":"7","author":"Jambo","year":"2014","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0055","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12977-016-0323-4","article-title":"Are T cells the only HIV-1 reservoir?","volume":"13","author":"Kandathil","year":"2016","journal-title":"Retrovirology"},{"key":"10.1016\/j.coviro.2019.03.004_bib0060","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.3748\/wjg.v24.i42.4728","article-title":"Liver as a target of human immunodeficiency virus infection","volume":"24","author":"Ganesan","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0065","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/infdis\/jit308","article-title":"The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence","volume":"208","author":"Yukl","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2019.03.004_bib0070","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/infdis\/jix039","article-title":"Human immunodeficiency virus persistence and T-cell activation in blood, rectal, and lymph node tissue in human immunodeficiency virus-infected individuals receiving suppressive antiretroviral therapy","volume":"215","author":"Khoury","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2019.03.004_bib0075","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/387183a0","article-title":"Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection","volume":"387","author":"Chun","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.03.004_bib0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/aid.2017.0254","article-title":"The spleen is an HIV-1 sanctuary during combined antiretroviral therapy","volume":"34","author":"Nolan","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.coviro.2019.03.004_bib0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/01.qai.0000230524.71717.14","article-title":"Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals","volume":"43","author":"Poles","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.coviro.2019.03.004_bib0090","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/QAD.0000000000001309","article-title":"HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy","volume":"31","author":"Gosselin","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2019.03.004_bib0095","doi-asserted-by":"crossref","DOI":"10.1038\/s41564-018-0335-z","article-title":"HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy","author":"Ganor","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0100","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/BF00184787","article-title":"Distribution of lymphocyte subsets and natural killer cells in the human body","volume":"70","author":"Westermann","year":"1992","journal-title":"Clin Investig"},{"key":"10.1016\/j.coviro.2019.03.004_bib0105","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/487439a","article-title":"HIV: shock and kill","volume":"487","author":"Deeks","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.03.004_bib0110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/1570162043484915","article-title":"Can HIV be cured? Mechanisms of HIV persistence and strategies to combat it","volume":"2","author":"Hamer","year":"2004","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.coviro.2019.03.004_bib0115","doi-asserted-by":"crossref","first-page":"E3659","DOI":"10.1073\/pnas.1617961114","article-title":"Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ART","volume":"114","author":"Wiegand","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2019.03.004_bib0120","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap9927","article-title":"HIV latency in isolated patient CD4(+) T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing","volume":"10","author":"Yukl","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2019.03.004_bib0125","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08431-7","article-title":"Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion","volume":"10","author":"Pinzone","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2019.03.004_bib0130","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006916","article-title":"Transcriptional and posttranscriptional regulation of HIV-1 gene expression","volume":"2","author":"Karn","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.coviro.2019.03.004_bib0135","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-virology-101416-041646","article-title":"The molecular basis for human immunodeficiency virus latency","volume":"4","author":"Mbonye","year":"2017","journal-title":"Annu Rev Virol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-981-13-0484-2_8","article-title":"The molecular biology of HIV latency","volume":"1075","author":"Khoury","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0145","doi-asserted-by":"crossref","first-page":"12291","DOI":"10.1128\/JVI.01383-08","article-title":"Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency","volume":"82","author":"Pearson","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1742-4690-10-67","article-title":"HIV-1 transcription and latency: an update","volume":"10","author":"Van Lint","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.coviro.2019.03.004_bib0155","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2174\/157016211798998736","article-title":"Control of HIV latency by epigenetic and non-epigenetic mechanisms","volume":"9","author":"Mbonye","year":"2011","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.coviro.2019.03.004_bib0160","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1371\/journal.ppat.0020068","article-title":"Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells","volume":"2","author":"Lassen","year":"2006","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.03.004_bib0165","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02158-18","article-title":"Posttranscriptional regulation of HIV-1 gene expression during replication and reactivation from latency by nuclear matrix protein MATR3","volume":"9","author":"Sarracino","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2019.03.004_bib0170","doi-asserted-by":"crossref","first-page":"9105","DOI":"10.1128\/JVI.78.17.9105-9114.2004","article-title":"Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo","volume":"78","author":"Lassen","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0175","doi-asserted-by":"crossref","first-page":"5665","DOI":"10.1128\/JVI.03158-15","article-title":"Short intracellular HIV-1 transcripts as biomarkers of residual immune activation in patients on antiretroviral therapy","volume":"90","author":"Ishizaka","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007357","article-title":"Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency","volume":"14","author":"Telwatte","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.03.004_bib0185","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.chom.2017.12.004","article-title":"Getting the \u201cKill\u201d into \u201cShock and Kill\u201d: strategies to eliminate latent HIV","volume":"23","author":"Kim","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2019.03.004_bib0190","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/COH.0000000000000279","article-title":"Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?","volume":"11","author":"Rasmussen","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.coviro.2019.03.004_bib0195","doi-asserted-by":"crossref","first-page":"42008","DOI":"10.1074\/jbc.M402124200","article-title":"Prostratin antagonizes HIV latency by activating NF-kappaB","volume":"279","author":"Williams","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2019.03.004_bib0200","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2174\/157016210793499312","article-title":"Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency","volume":"8","author":"Perez","year":"2010","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.coviro.2019.03.004_bib0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168027","article-title":"Euphorbia Kansui reactivates latent HIV","volume":"11","author":"Cary","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2019.03.004_bib0210","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1089\/aid.2006.22.854","article-title":"HIV type 1 inhibition by protein kinase C modulatory compounds","volume":"22","author":"Warrilow","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.coviro.2019.03.004_bib0215","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.virol.2014.05.033","article-title":"Reactivation of latent HIV-1 by new semi-synthetic ingenol esters","volume":"462\u2013463","author":"Pandelo Jose","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2019.03.004_bib0220","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1128\/AAC.01077-15","article-title":"Ex vivo bioactivity and HIV-1 latency reversal by Ingenol Dibenzoate and Panobinostat in resting CD4(+) T cells from aviremic patients","volume":"59","author":"Spivak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2019.03.004_bib0225","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1097\/QAD.0000000000001064","article-title":"Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy","volume":"30","author":"Gutierrez","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2019.03.004_bib0230","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-02634-y","article-title":"The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1","volume":"7","author":"Lopez-Huertas","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2019.03.004_bib0235","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01931-17","article-title":"Maraviroc is associated with latent HIV-1 reactivation through NF-kappaB activation in resting CD4(+) T cells from HIV-Infected Individuals on suppressive antiretroviral therapy","author":"Madrid-Elena","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0240","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1016\/S2352-3018(15)00226-X","article-title":"Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study","volume":"2","author":"Elliott","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.coviro.2019.03.004_bib0245","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1097\/QAD.0000000000001937","article-title":"Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1","volume":"32","author":"Chang","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2019.03.004_bib0250","article-title":"Sex-based differences in HIV-1 reservoir activity and residual immune activation","author":"Scully","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2019.03.004_bib0255","doi-asserted-by":"crossref","first-page":"E7795","DOI":"10.1073\/pnas.1803468115","article-title":"Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir","volume":"115","author":"Das","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2019.03.004_bib0260","article-title":"Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals","author":"Moron-Lopez","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2019.03.004_bib0265","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1073\/pnas.1522675113","article-title":"Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo","volume":"113","author":"Simonetti","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2019.03.004_bib0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06843-5","article-title":"A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation","volume":"9","author":"Reeves","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2019.03.004_bib0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005349","article-title":"TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection","volume":"12","author":"Chew","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.03.004_bib0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005761","article-title":"CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART","volume":"12","author":"Fromentin","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.03.004_bib0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005661","article-title":"Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection","volume":"12","author":"Hoffmann","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.03.004_bib0290","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","article-title":"Toll-like receptor control of the adaptive immune responses","volume":"5","author":"Iwasaki","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0295","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao4521","article-title":"TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy","volume":"10","author":"Lim","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2019.03.004_bib0305","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nature20583","article-title":"Ad26\/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys","volume":"540","author":"Borducchi","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.03.004_bib0310","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.03.004_bib0315","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cix201","article-title":"Short-course TLR9 agonist treatment impacts innate immunity and plasma viremia in individuals with HIV infection","author":"Vibholm","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2019.03.004_bib0320","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.chom.2016.07.015","article-title":"Single-cell characterization of viral translation-competent reservoirs in HIV-infected individuals","volume":"20","author":"Baxter","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2019.03.004_bib0325","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nri.2017.112","article-title":"Immune checkpoint blockade in infectious diseases","volume":"18","author":"Wykes","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0330","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.03.004_bib0335","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.03.004_bib0340","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/ni1515","article-title":"Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction","volume":"8","author":"Kaufmann","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0345","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1182\/blood-2006-09-044826","article-title":"PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors","volume":"109","author":"Zhang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2019.03.004_bib0350","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.4049\/jimmunol.1402176","article-title":"The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects","volume":"194","author":"Tian","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0355","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122940","article-title":"Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV","volume":"3","author":"Mylvaganam","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.coviro.2019.03.004_bib0360","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature07662","article-title":"Enhancing SIV-specific immunity in vivo by PD-1 blockade","volume":"458","author":"Velu","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.03.004_bib0365","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1172\/JCI60612","article-title":"PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques","volume":"122","author":"Dyavar Shetty","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2019.03.004_bib0370","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1097\/QAD.0000000000001217","article-title":"Programed death-1\/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab)","volume":"30","author":"Gill","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2019.03.004_bib0375","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1182\/blood-2006-04-010637","article-title":"CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques","volume":"108","author":"Hryniewicz","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2019.03.004_bib0380","doi-asserted-by":"crossref","DOI":"10.1038\/nm.4113","article-title":"PD-1 and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals","author":"Banga","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.03.004_bib0385","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/QAD.0000000000001849","article-title":"Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency","volume":"32","author":"Evans","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2019.03.004_bib0390","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08798-7","article-title":"PD-1 blockade potentiates HIV latency reversal ex vivo in CD4(+) T cells from ART-suppressed individuals","volume":"10","author":"Fromentin","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2019.03.004_bib0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211112","article-title":"Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART","volume":"14","author":"Bui","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2019.03.004_bib0400","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/QAD.0000000000000562","article-title":"Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma","volume":"29","author":"Wightman","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2019.03.004_bib0405","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdx696","article-title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","volume":"29","author":"Guihot","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0410","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/annonc\/mdy259","article-title":"Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection","volume":"29","author":"Scully","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0415","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/cid\/cis383","article-title":"Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I\/IIa randomized, placebo-controlled, multicenter study","volume":"55","author":"Levy","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2019.03.004_bib0420","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/QAD.0000000000000894","article-title":"Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial","volume":"30","author":"Katlama","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2019.03.004_bib0425","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1182\/blood-2012-11-465625","article-title":"Interleukin-7 promotes HIV persistence during antiretroviral therapy","volume":"121","author":"Vandergeeten","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2019.03.004_bib0430","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/bloodadvances.2017012971","article-title":"The human IL-15 superagonist ALT-803 directs SIV-specific CD8(+) T cells into B-cell follicles","volume":"2","author":"Webb","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.coviro.2019.03.004_bib0435","article-title":"Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes","volume":"14","author":"Watson","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.03.004_bib0440","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nm.3781","article-title":"B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers","volume":"21","author":"Fukazawa","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.03.004_bib0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005545","article-title":"A subset of latency-reversing agents expose HIV-infected resting CD4+ T-cells to recognition by cytotoxic T-lymphocytes","volume":"12","author":"Jones","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.03.004_bib0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005063","article-title":"An in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified Bryostatin-1+JQ1 and ingenol-B+JQ1 to potently reactivate viral gene expression","volume":"11","author":"Darcis","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.03.004_bib0455","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1172\/JCI80142","article-title":"Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations","volume":"125","author":"Laird","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2019.03.004_bib0460","doi-asserted-by":"crossref","first-page":"11091","DOI":"10.1128\/JVI.76.21.11091-11103.2002","article-title":"Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies","volume":"76","author":"Quivy","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006093","article-title":"Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection","volume":"4","author":"Reuse","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2019.03.004_bib0470","doi-asserted-by":"crossref","first-page":"5958","DOI":"10.1128\/JVI.00161-10","article-title":"Combinatorial latency reactivation for HIV-1 subtypes and variants","volume":"84","author":"Burnett","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0475","doi-asserted-by":"crossref","DOI":"10.1038\/srep16445","article-title":"Synergistic activation of latent HIV-1 expression by novel histone deacetylase inhibitors and Bryostatin-1","volume":"5","author":"Martinez-Bonet","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2019.03.004_bib0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005066","article-title":"Synergistic reactivation of latent HIV expression by ingenol-3-angelate, PEP005, targeted NF-kB signaling in combination with JQ1 induced p-TEFb activation","volume":"11","author":"Jiang","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.03.004_bib0485","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","article-title":"Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B\/2A trial","volume":"3","author":"Leth","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.coviro.2019.03.004_bib0490","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01484-15","article-title":"Innate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostat","author":"Olesen","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0495","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/150845","article-title":"Apoptosis and molecular targeting therapy in cancer","volume":"2014","author":"Hassan","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.coviro.2019.03.004_bib0500","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1128\/JVI.03179-15","article-title":"Prime, shock, and kill: priming CD4 T cells from HIV patients with a BCL-2 antagonist before HIV reactivation reduces HIV reservoir size","volume":"90","author":"Cummins","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0505","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.chom.2018.09.007","article-title":"SMAC mimetics induce autophagy-dependent apoptosis of HIV-1-infected resting memory CD4+ T cells","volume":"24","author":"Campbell","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2019.03.004_bib0510","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fmicb.2018.02022","article-title":"Combination of a latency-reversing agent with a Smac mimetic minimizes secondary HIV-1 infection in vitro","volume":"9","author":"Hattori","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.coviro.2019.03.004_bib0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013121","article-title":"Targeting the PI3K\/Akt cell survival pathway to induce cell death of HIV-1 infected macrophages with alkylphospholipid compounds","volume":"5","author":"Lucas","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2019.03.004_bib0520","article-title":"Novel PI3K\/Akt inhibitors screened by the cytoprotective function of human immunodeficiency virus type 1 Tat","volume":"6","author":"Kim","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2019.03.004_bib0525","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nm.4124","article-title":"Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation","volume":"22","author":"Li","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.03.004_bib0530","doi-asserted-by":"crossref","DOI":"10.3791\/58016","article-title":"Amplification of near full-length HIV-1 proviruses for next-generation sequencing","author":"Hiener","year":"2018","journal-title":"J Vis Exp"},{"key":"10.1016\/j.coviro.2019.03.004_bib0535","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nmeth.3320","article-title":"Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques","volume":"12","author":"Santangelo","year":"2015","journal-title":"Nat Methods"},{"key":"10.1016\/j.coviro.2019.03.004_bib0540","doi-asserted-by":"crossref","DOI":"10.7326\/M14-1027","article-title":"Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases","author":"Henrich","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coviro.2019.03.004_bib0545","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMc1413931","article-title":"Viremic relapse after HIV-1 remission in a perinatally infected child","volume":"372","author":"Luzuriaga","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2019.03.004_bib0550","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature14053","article-title":"Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations","volume":"517","author":"Deng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.03.004_bib0555","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/infdis\/jiy479","article-title":"The Control of HIV After Antiretroviral medication pause (CHAMP) study: posttreatment controllers identified from 14 clinical studies","volume":"218","author":"Namazi","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2019.03.004_bib0560","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093330","article-title":"Measuring turnover of SIV DNA in resting CD4+ T cells using pyrosequencing: implications for the timing of HIV eradication therapies","volume":"9","author":"Reece","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2019.03.004_bib0565","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1473-3099(13)70043-4","article-title":"The search for an HIV cure: tackling latent infection","volume":"13","author":"Kent","year":"2013","journal-title":"Lancet Infect Dis"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625719300082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625719300082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:20:50Z","timestamp":1783632050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625719300082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":113,"alternative-id":["S1879625719300082"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2019.03.004","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Between a shock and a hard place: challenges and developments in HIV latency reversal","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2019.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}